01- The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients
The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with no history of MI or stroke.
Read also HERE
02- Estimating the Risk of Infection for Healthcare Personnel
Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not uniform for all corners of earth, and they do not indicate that being on the front line necessarily entails higher risk.
Read also HERE
03- Leaflet Thickening and Immobility in Evolut Low Risk
Leaflet thickening and immobility caused by thrombosis have been reported for both surgical and transcatheter bioprostheses.
Read also HERE
04- Stenting of Lipid-Rich vs Fibrous and calcified Plaques: Different Prognosis?
Coronary PCI with contemporary drug eluting stents (DES) in lipidic-rich plaques were not associated with increased periprocedural events at long term compared against plaques with no significant lipidic composition.
Read also HERE
05- Covid-19 and Unaccounted Collateral Damage
Dr Metzler and collaborators carried out a retrospective search to find out the impact of the Covid-19 pandemic on diagnosis and treatment of acute coronary syndromes during March 2020 in Austria. Basically, they tried to account for the collateral damage we all imagine, but no government reports.
Read also HERE
06- Multiple vs. Culprit vessel MI in Cardiogenic Shock: Anything New?
The Shock Trial, the one that set revascularization as the standard strategy to treat all STEMI and cardiogenic shock lesions, had not been discussed for nearly 20 years.
Read also HERE
07- Non-Invasive Diagnosis of Coronary Spasm: Can We Recommend it?
Conventional non-invasive testing to detect obstructive coronary artery disease (CAD) by induced myocardial ischemia are not useful to diagnose epicardial or microvascular coronary artery spasm.
Read also HERE
08- Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment
Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from a very early intervention strategy.
Read also HERE
09- Contained Annulus Rupture after TAVR: What Should We Do?
Aortic annulus rupture is a catastrophic event that presents in nearly 0.9% of cases, but there is another entity called contained annulus rupture, associated to oversized devices and annulus calcification and diagnosed with CT angiography, with up to 5% frequency.
Read also HERE
10- SOLACI Peripheral | Clinical Case Discussion
SOLACI’s Department of Peripheral Endovascular Interventions is promoting the analysis of challenging clinical cases on peripheral interventions so as to foster the participation and engagement of all SOLACI members.
Read also HERE
Get the latest scientific articles on interventional cardiologySubscribe to our weekly newsletter
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
